Amplia Therapeutics Limited

ASX:ATX.AX

0.15 (AUD) • At close October 23, 2024
Bedrijfsnaam Amplia Therapeutics Limited
Symbool ATX.AX
Munteenheid AUD
Prijs 0.15
Beurswaarde 41,219,700
Dividendpercentage 0%
52-weken bereik 0.055 - 0.18
Industrie Biotechnology
Sector Healthcare
CEO Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.
Website https://www.ampliatx.com

An error occurred while fetching data.

Over Amplia Therapeutics Limited

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has

Vergelijkbare Aandelen

ECS Botanics Holdings Ltd logo

ECS Botanics Holdings Ltd

ECS.AX

0.017 AUD

ImExHS Limited logo

ImExHS Limited

IME.AX

0.44 AUD

Immuron Limited logo

Immuron Limited

IMC.AX

0.077 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)